This research is in the early stages, but it sounds promising: a new drug agent ZEN-3694 and enzalutamide have been used in combination to halt disease progression. The new element is that dosing is dynamically changed over the course of the therapy, whereby in this case, some patients were given dramatically lower doses of the drugs when they responded and their cancers shrank: news.nus.edu.sg/press-relea...
Arthur
